沃雷蒂基内帕尔沃维克 (Voretigene Neparvovec) 的现实结果:一个单一中心连续的案例系列
Assad Jalil1, Mariantonia Ferrara2,3, Myrta Lippera4
1Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK. assad.jalil@mft.nhs.uk.
Eye (London, England)
|February 3, 2025
概括
亚视网膜Voretigene Neparvovec (VN) 基因疗法改善了遗传视网膜衰变 (IRD) 患者的视力. 虽然胆管缩 (CRA) 发生在手术后,但其功能影响是最小的.
科学领域:
- 眼科医生 眼科 眼科
- 遗传学 是一个遗传学.
- 视网膜疾病 视网膜疾病
背景情况:
- 遗传性视网膜变 (IRDs) 是视力丧失的重要原因之一.
- 基因疗法为特定的IRD提供了一个有前途的治疗途径.
- RPE65突变是已知的IRD的遗传原因,可以接受基因治疗.
研究的目的:
- 为了评估基因治疗的功能和解剖结果,Voretigene Neparvovec (VN) 基因疗法.
- 在英国一组IRD患者中评估VN的安全性和有效性.
- 报告VN治疗后的长期结果.
主要方法:
- 8名患有RPE65相关IRD的患者 (14只眼睛) 的回顾性病例系列,这些患者接受了皮VN治疗.
- 在治疗前和治疗后进行了全面的眼科检查,包括视觉敏度,色彩视觉和OCT,长达24个月.
- 分析了功能和解剖学参数,以评估治疗结果.
主要成果:
- 平均视力敏度在治疗后改善了2条线.
- 大多数功能测试显示改善,大多数患者的视网膜厚度稳定.
- 在3名患者中观察到视网膜切除部位的胆管缩 (CRA),其功能影响有限.
结论:
- 亚视网膜VN基因疗法在改善RPE65相关的IRD视觉功能方面是有效的.
- CRA是一种常见的术后并发症,但通常对视觉结果的影响有限.
- 对符合条件的IRD患者来说,VN疗法是一个可行的治疗选择.
相关概念视频
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:16Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
01:11Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
01:19Pharmacovigilance
769
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
769
01:28Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131